Ceribell: Strong Top-Line Outperformance and Expanding Growth Vectors Underpin Buy Rating

In a report released today, Josh Jennings from TD Cowen reiterated a Buy rating on Ceribell, Inc., with a price target of $29.00.

Josh Jennings has given his Buy rating due to a combination of factors including Ceribell’s strong top-line outperformance and robust margin profile. The company delivered quarterly revenue growth well above consensus, driven by rapid adoption in its core seizure monitoring market, record sequential account additions, and a healthy mix of product and subscription growth that supports high gross margins.

Jennings also points to management’s 2026 revenue outlook that aligns with Street expectations while leaving room for upside from new growth vectors. He highlights expanding penetration in adult and VA settings, the planned push into pediatric and neonatal monitoring later this year, and increased productivity from a scaled commercial team, all supported by a solid cash position that helps fund growth despite current losses.